Surrozen Inc Ordinary Shares SRZN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Surrozen Reports Third Quarter 2026 Financial Results and Provides Business Update
Surrozen to Present at Upcoming Healthcare Investor Conference
Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
Surrozen to Present at Upcoming Healthcare Investor Conferences
Trading Information
- Previous Close Price
- $31.88
- Day Range
- $30.53–32.45
- 52-Week Range
- $12.12–37.83
- Bid/Ask
- $31.66 / $31.78
- Shares Outstanding
- 19.06M
- Market Cap
- $554.07M
- Volume/Avg
- 134,041 / 534,398
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 32.94
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 44
- Website
- https://www.surrozen.com
Valuation
Metric | SRZN |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 32.94 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | SRZN |
|---|---|
Quick Ratio | 7.37 |
Current Ratio | 7.56 |
Interest Coverage | — |
Quick Ratio
SRZN
Profitability
Metric | SRZN |
|---|---|
Return on Assets (Normalized) | −36.49% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
SRZN
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|Z$%f$h | LOCK|TddSd | $139B | |||
| Moderna Inc MRNA | LOCK|^b@l<># | LOCK|TR | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|p<C>>!$ | LOCK|Xc@P | $99B | |||
| argenx SE ADR ARGX | LOCK|l<<qS! | LOCK|Z>c | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|ck#^f< | LOCK|Zr | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|b&@Pf$W | LOCK|$#>K | $31B | |||
| Incyte Corp INCY | LOCK|>PN?y@ | LOCK|wb | $25B | |||
| BioNTech SE ADR BNTX | LOCK|tYb<WVP | LOCK|Z> | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|Wy?j$GF | LOCK|>M%? | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|x<Hr@z | LOCK|w!$ | $16B |
United States